Windward Bio–Omega Funds: investment, 202501 financing round Series A totalling $200m incl co-investor Omega Funds |
2025-01-10 |
Windward Bio–OrbiMed: investment, 202501 financing round Series A totalling $200m incl co-lead investor OrbiMed |
2025-01-10 |
Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners |
2025-01-10 |
Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital |
2025-01-10 |
Windward Bio–RTW Investments: investment, 202501 financing round Series A totalling $200m incl co-investor RTW Investments |
2025-01-10 |
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One |
2025-01-10 |
Boehringer–Lonza: ADC technology, 202501– license to Synaffix ADC technology €na upfront + $1.3b milestones plus royalties |
2025-01-09 |
Graph Therapeutics–SEVERAL: investment, 202501 pre-seed financing round $3.1m led by Squareone + Merantix Capital |
2025-01-09 |
Numab–Cormorant Asset Management: investment, 202501 financing round Series C extension totalling CHF50m incl existing + co-lead investor Cormorant AM |
2025-01-09 |
Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m |
2025-01-09 |
Alesta Therapeutics–Novartis: investment, 202501 financing round Series A totalling €65m incl co-investor Novartis Venture Fund |
2025-01-08 |
Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures |
2025-01-08 |
Alesta Therapeutics–Vetter: investment, 202501 financing round Series A totalling €65m incl co-investor RV Invest |
2025-01-08 |
Orbis Medicines–Cormorant Asset Management: investment, 202501 financing round Series totalling €90m incl new + co-investor Cormorant |
2025-01-06 |
Orbis Medicines–Denmark (govt): investment, 202501 financing round Series totalling €90m incl new + co-investor EIFO |
2025-01-06 |
Orbis Medicines–Forbion: investment, 202501 financing round Series totalling €90m incl existing + co-investor Forbion |
2025-01-06 |
Orbis Medicines–Lilly: investment, 202501 financing round Series totalling €90m incl new + co-investor Eli Lilly |
2025-01-06 |
Orbis Medicines–New Enterprise Associates: investment, 202501 financing round Series totalling €90m incl new + lead investor NEA |
2025-01-06 |
Orbis Medicines–Novo Group: investment, 202501 financing round Series totalling €90m incl existing + co-investor Novo Holdings |
2025-01-06 |
Orbis Medicines–SEVERAL: investment, 202501 financing round Series €90m led by NEA |
2025-01-06 |
Roche–Innovent Biologics: antibody-drug conjugate, 202501– collab + excl ww license to IBI3009 with $80m upfront + $1b milestones plus royalties |
2025-01-02 |
Gemma Biotherapeutics–Earlybird: investment, 202412 seed financing round totalling $34m incl co-lead investor Earlybird Venture Capital |
2024-12-23 |
Gemma Biotherapeutics–SEVERAL: investment, 202412 seed financing round $34m led by Doube Point Ventures + Bioluminescence Ventures + Earlybird VC |
2024-12-23 |
Univ Zurich–Bruker: NMR spectrometer, 202412 supply 1.2 GHz Ascend NMR spectrometer to Swiss High-field NMR Facility at UZH |
2024-12-20 |
Novartis–BioAge Labs: drug target discovery, 202412– collab multi-year $20m upfront + $530m milestones identify targets for age-related diseases |
2024-12-18 |
HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED |
2024-12-17 |
Formo Bio–EU (govt): credit, 202412– venture debt loan €35m from EIB |
2024-12-16 |
Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit |
2024-12-16 |
RhyGaze–Alphabet: investment, 202412 financing round Series A totalling $86m incl new + lead investor GV |
2024-12-13 |
RhyGaze–ARCH Venture: investment, 202412 financing round Series A totalling $86m incl new + co-investor ARCH Venture Partners |
2024-12-13 |
RhyGaze–BioGeneration Ventures: investment, 202412 financing round Series A totalling $86m incl existing + co-investor BGV |
2024-12-13 |
RhyGaze–F-Prime: investment, 202412 financing round Series A totalling $86m incl new + co-investor F-Prime Capital |
2024-12-13 |
RhyGaze–Novartis: investment, 202412 financing round Series A totalling $86m incl existing + co-investor NVF |
2024-12-13 |
RhyGaze–SEVERAL: investment, 202412 financing round Series A $86m led by GV |
2024-12-13 |
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments |
2024-12-12 |
Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi |
2024-12-10 |
Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund |
2024-12-09 |
Ariceum Therapeutics–Eckert & Ziegler: radionuclides, 202412– supply agreem ww for Ac-225 + Lu-177 to Ariceum |
2024-12-05 |
Bruker–Ion Opticks: liquid chromatography, 202412– supply costum chromatography column for MS-based proteomic services to Biognosys |
2024-12-05 |
Antag Therapeutics–Pictet: investment, 202412 financing round Series A totalling €80m incl co-investor Pictet |
2024-12-04 |
Antag Therapeutics–SEVERAL: investment, 202412 financing round Series A €80m led by Versant Ventures |
2024-12-04 |
Antag Therapeutics–Versant Ventures: investment, 202412 financing round Series A totalling €80m incl lead investor Versant Ventures |
2024-12-04 |
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures |
2024-12-04 |
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures |
2024-12-04 |
ViveBiotech–Ampersand: investment, 202412 growth equity investment from Ampersand Capital Partners |
2024-12-04 |
Eppendorf–DataHow: laboratory software, 202412– collab strategic integration of DataHowLab s/w with BioNSight cloud |
2024-12-02 |
Carl Roth–Bio Inx: bioinks, 202411– distribution ww of entire portfolio of bioinks of Bio Inx by Carl Roth |
2024-11-27 |
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures |
2024-11-26 |
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP |
2024-11-26 |
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital |
2024-11-26 |
Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP |
2024-11-26 |
Eisbach Bio–Texas (govt): grant, 202411 CPRIT grant $4.75m to support Ph1/2 study of EIS-12656 at MD Anderson |
2024-11-26 |
Grifols–Cradle Bio: protein engineering, 202411 supply existent Grifols is user of AI-based protein engineering platform |
2024-11-26 |
JnJ–Cradle Bio: protein engineering, 202411 supply existent JnJ Innovative Medicine is user of AI-based protein engineering platform |
2024-11-26 |
Kyan Health–Amplo: investment, <202411 seed financing round totalling $4m incl lead investor Amplo VC |
2024-11-26 |
Kyan Health–Founderful: investment, 202411 financing round Series A totalling $12.7m incl co-investor Founderful |
2024-11-26 |
Kyan Health–GreyMatter Capital: investment, 202411 financing round Series A totalling $12.7m incl co-investor GreyMatter Capital |
2024-11-26 |
Kyan Health–Joyance Partners: investment, 202411 financing round Series A totalling $12.7m incl co-investor Joyance Partners |
2024-11-26 |
Kyan Health–OTHER: investment, 202411 financing round Series A totalling $12.7m incl several angel investors |
2024-11-26 |
Kyan Health–Schwabe: investment, 202411 financing round Series A totalling $12.7m incl co-investor NaturalX Health Ventures |
2024-11-26 |
Kyan Health–SEVERAL: investment, 202411 financing round Series A $12.7m led by Swisscom Ventures |
2024-11-26 |
Kyan Health–SEVERAL: investment, <202411 seed financing round $4m led by Amplo VC |
2024-11-26 |
Kyan Health–Swisscom: investment, 202411 financing round Series A totalling $12.7m incl lead investor Swisscom Ventures |
2024-11-26 |
Novo Group–Cradle Bio: protein engineering, 202411 supply existent Novo Nordisk is user of AI-based protein engineering platform |
2024-11-26 |
Novonesis–Cradle Bio: protein engineering, 202411 supply existent Novonesis is user of AI-based protein engineering platform |
2024-11-26 |
Poseida Therapeutics–Roche: investment, 202411– acquisition $1b in cash + up to $500k in CVRs by Roche |
2024-11-26 |
Baccinex–Adragos Pharma: investment, 202411 acquisition €na of Baccinex by Adragos Pharma |
2024-11-25 |
Bico–RAG: investment, 202411 acquisition €26m of Nanoscribe from Bico Group by LAB14 GmbH |
2024-11-21 |
Kate Therapeutics–Novartis: investment, 202411 acquisition up to $1.1b incl upfront cash payment + milestones by Novartis |
2024-11-21 |
Pep2Tango Therapeutics–Versant Venures: investment, 202411 investment round €na with Versant Ventures |
2024-11-21 |
Evotec–Halozyme: investment, 202411 acquisition €2b unsolicited + non-binding cash offer at €11/share refused + withdrawn NOT REALISED |
2024-11-14 |
Andera Partners–MC Services: public relations, 202411 service existent by MC Services |
2024-11-13 |
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones |
2024-11-13 |
Centogene–Charme Capital Partners: investment, 202411–202503 acquisition €8.7m of sole operating subsidiary Centogene GmbH by Charme Capital |
2024-11-13 |
Invios–MC Services: public relations, 202410 service existent by MC Services |
2024-11-13 |
Alentis Therapeutics–Avego Bioscience Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Avego BC |
2024-11-12 |
Alentis Therapeutics–Bellevue: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor BB Pureos |
2024-11-12 |
Alentis Therapeutics–Catalio Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Catalio Capital |
2024-11-12 |
Alentis Therapeutics–France (govt): investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Bpifrance InnoBio 2 Fund |
2024-11-12 |
Alentis Therapeutics–Frazier: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Frazier Life Sciences |
2024-11-12 |
Alentis Therapeutics–Jeito Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Jeito Capital |
2024-11-12 |
Alentis Therapeutics–Longitude Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor Longitude Capital |
2024-11-12 |
Alentis Therapeutics–Morningside: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Morningside VI |
2024-11-12 |
Alentis Therapeutics–Novo Group: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Novo Holdings |
2024-11-12 |
Alentis Therapeutics–OrbiMed: investment, 202411 financing round Series D totalling $181.4m incl lead investor OrbiMed |
2024-11-12 |
Alentis Therapeutics–Piper Heartland Healthcare Capital: investment, 202411 financing round Series D totalling $181.4m incl new + co-investor PHHC |
2024-11-12 |
Alentis Therapeutics–RA Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor RA Capital Management |
2024-11-12 |
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital |
2024-11-12 |
Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests |
2024-11-12 |
Mediaire–Berlin (govt): investment, 202411 financing round totalling €12m incl co-investor IBB Ventures |
2024-11-12 |
Mediaire–G8Way Ventures: investment, 202411 financing round totalling €12m incl existing + co-investor Gateway Ventures |
2024-11-12 |
Mediaire–High-Tech Gründerfonds: investment, 202411 financing round totalling €12m incl existing + co-investor HTGF |
2024-11-12 |
Mediaire–LBO France: investment, 202411 financing round totalling €12m incl lead investor LBO France |
2024-11-12 |
Mediaire–LIFTT (IT): investment, 202411 financing round totalling €12m incl existing + co-investor LIFTT |
2024-11-12 |
Mediaire–SEVERAL: investment, 202411 financing round €12m led by LBO France |
2024-11-12 |
Mediaire–Wille Finance: investment, 202411 financing round totalling €12m incl co-investor Wille Finance |
2024-11-12 |
Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF |
2024-11-12 |
Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF |
2024-11-12 |
Complihealth–Bertelsmann: investment, <=202411 investment by new investor Bertelsmann Investments in Guardoc Health |
2024-11-07 |